Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

BNP-7787 (BioNumerik/Baxter Oncology/Grelan).

R Todd Reilly¹

¹The Johns Hopkins School of Medicine, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street Room 4M08, Baltimore, MD 21231, USA. reilly@jhmi.edu

Idrugs : the Investigational Drugs Journal

|January 20, 2004

Summary

BNP-7787 is being developed to reduce the toxicity of cisplatin and carboplatin chemotherapy. This novel therapeutic aims to improve cancer patient outcomes by mitigating side effects from these common treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity.

International journal of cancer·2009

Same author

An immunotolerant HER-2/neu transgenic mouse model of metastatic breast cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2008

Same author

213Bi (alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model.

Cancer research·2008

Same author

Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs.

The Journal of clinical investigation·2008

Same author

Ductal access for prevention and therapy of mammary tumors.

Cancer research·2006

Same author

OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen.

Journal of immunology (Baltimore, Md. : 1950)·2006

Area of Science:

Oncology
Pharmacology

Background:

Cisplatin and carboplatin are widely used platinum-based chemotherapy agents.
These drugs are associated with significant dose-limiting toxicities, impacting patient quality of life and treatment adherence.

Purpose of the Study:

To evaluate the efficacy of BNP-7787 in reducing chemotherapy-induced toxicity.
To assess the potential of BNP-7787 as a supportive therapy in cancer treatment regimens involving cisplatin or carboplatin.

Main Methods:

Preclinical studies and/or clinical trials investigating the administration of BNP-7787 alongside cisplatin and carboplatin.
Assessment of specific toxicity markers and patient-reported outcomes.

Main Results:

Preliminary data suggests BNP-7787 may mitigate certain toxicities associated with cisplatin and carboplatin.
Further investigation is warranted to confirm the safety and efficacy profile.

Conclusions:

BNP-7787 shows promise as a novel agent for managing chemotherapy-induced side effects.
This development could lead to improved tolerability of platinum-based chemotherapy in cancer patients.

Related Experiment Videos